Singlera Genomics, a pioneer in DNA methylation technologies for genetic diagnosis, announced a major research and distribution deal with EU-based medical company Pure Medical.

 

The partnership will leverage Singlera’s mTitan and mGuard platforms, which screen circulating cell-free DNA to detect cancer signals—often before symptoms appear. The platforms have been successfully used to non-invasively detect methylation haplotypes linked to esophageal, colorectal, gastric, lung, liver, and pancreatic cancers.

 

Under the agreement, Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies. They will also collaborate on the commercial distribution of mTitan- and mGuard-based assays in several European countries.

 

“We are excited to partner with Pure Medical to focus on cancer detection and surveillance across western Europe, including colorectal and pancreatic cancer,” said Qiang Liu, COO and co-founder of Singlera Genomics. 

 

“This distribution agreement represents an important step in our European business strategy to bring inexpensive early cancer detection and monitoring to the global patient population; we hope that Singlera’s methylation products can give clinicians an important tool for faster detection, diagnosis, and treatment of cancer.”

 

Maarten van Dijk, CEO of Pure Medical, added, “We are pleased to be working with Singlera Genomics. We are already engaged in research collaborations with academic and healthcare institutions across the UK and Europe, and are working toward the earliest possible commercialization of Singlera’s colorectal and pancreatic cancer products across seven EU countries. 

 

"These innovative, non-invasive technologies have the potential to support earlier detection and more effective monitoring of colorectal and pancreatic cancer, and we are encouraged by what our existing engagement with healthcare systems can bring in translating this innovation into real-world clinical benefit.”